• LAST PRICE
    116.2050
  • TODAY'S CHANGE (%)
    Trending Up0.1750 (0.1508%)
  • Bid / Lots
    116.1700/ 1
  • Ask / Lots
    116.2400/ 2
  • Open / Previous Close
    116.3000 / 116.0300
  • Day Range
    Low 116.0900
    High 116.7100
  • 52 Week Range
    Low 99.1400
    High 134.6300
  • Volume
    239,086
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 116.03
TimeVolumeMRK
09:32 ET4692116.12
09:34 ET125833116.71
09:36 ET31939116.33
09:38 ET18454116.19
09:39 ET16625116.255
09:41 ET2187116.205
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMRK
Merck & Co Inc
294.1B
21.6x
-43.23%
United StatesABBV
AbbVie Inc
347.1B
65.9x
-6.05%
United StatesAZN
AstraZeneca PLC
263.8B
41.5x
+17.52%
United StatesNVS
Novartis AG
257.8B
24.1x
-5.59%
United StatesRHHBY
Roche Holding AG
271.2B
21.4x
+3.28%
United StatesPFE
Pfizer Inc
164.5B
-62.6x
-7.10%
As of 2024-08-22

Company Information

Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand. Its lead candidate, Restoret, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway.

Contact Information

Headquarters
2000 Galloping Hill RoadKENILWORTH, NJ, United States 07033
Phone
908-740-4000
Fax
908-423-1987

Executives

Chairman of the Board, President, Chief Executive Officer
Robert Davis
Chief Financial Officer, Executive Vice President
Caroline Litchfield
Chief Human Resource Officer
Betty Larson
Executive Vice President, Chief Information and Digital Officer
David Williams
Executive Vice President, General Counsel, Corporate Secretary
Jennifer Zachary

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$294.1B
Revenue (TTM)
$62.5B
Shares Outstanding
2.5B
Dividend Yield
2.65%
Annual Dividend Rate
3.0800 USD
Ex-Dividend Date
09-16-24
Pay Date
10-07-24
Beta
0.40
EPS
$5.39
Book Value
$14.84
P/E Ratio
21.6x
Price/Sales (TTM)
4.7
Price/Cash Flow (TTM)
16.5x
Operating Margin
24.75%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.